Cargando…

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein degradation tool developed in recent years that can ubiquitinate the target proteins through the ubiquitin-proteasome system (UPS) to achieve an effect on tumor growth. A number of literature studies on PROTAC tech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Si-Min, Dong, Jinyun, Xu, Zhi-Yuan, Cheng, Xiang-Dong, Zhang, Wei-Dong, Qin, Jiang-Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138175/ https://www.ncbi.nlm.nih.gov/pubmed/34025443 http://dx.doi.org/10.3389/fphar.2021.692574

Ejemplares similares

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

Platycodin-D exerts its anti-cancer effect by promoting c-Myc protein ubiquitination and degradation in gastric cancer
por: Xu, Qianqian, et al.
Publicado: (2023)

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
por: Mancarella, Caterina, et al.
Publicado: (2023)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

Targeting β-Catenin Signaling by Natural Products for Cancer Prevention and Therapy
por: Yu, Wen-Kai, et al.
Publicado: (2020)

Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
por: Yuan, Minghua, et al.
Publicado: (2021)

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
por: Kelm, Jeremy M., et al.
Publicado: (2023)

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
por: Sincere, Nuwayo Ishimwe, et al.
Publicado: (2023)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

PROTAC targeted protein degraders: the past is prologue
por: Békés, Miklós, et al.
Publicado: (2022)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

BacPROTACs mediate targeted protein degradation in bacteria
por: Morreale, Francesca E., et al.
Publicado: (2022)

Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer
por: Li, Haobin, et al.
Publicado: (2022)

Protein degradation technology: a strategic paradigm shift in drug discovery
por: Li, Haobin, et al.
Publicado: (2021)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

PROTACs: Walking through hematological malignancies
por: Bou Malhab, Lara J., et al.
Publicado: (2023)

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
por: Naito, Mikihiko, et al.
Publicado: (2019)

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
por: Alabi, Shanique B., et al.
Publicado: (2021)

Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
por: Wang, Huifang, et al.
Publicado: (2023)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
por: Kim, Hanbyeol, et al.
Publicado: (2022)

RNA‐PROTACs: Degraders of RNA‐Binding Proteins
por: Ghidini, Alice, et al.
Publicado: (2020)

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
por: Gao, Jing, et al.
Publicado: (2022)

Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
por: Jin, Jinmei, et al.
Publicado: (2022)

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
por: Yu, De-Hua, et al.
Publicado: (2020)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

ERα-Targeting PROTAC as a Chemical Knockdown Tool to Investigate the Estrogen Receptor Function in Rat Menopausal Arthritis
por: Duan, Li, et al.
Publicado: (2021)

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
por: Jin, Jinmei, et al.
Publicado: (2020)

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
por: Liu, Jing, et al.
Publicado: (2021)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
por: Ishikawa, Minoru, et al.
Publicado: (2020)

Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
por: Ruffilli, Camilla, et al.
Publicado: (2022)

Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
por: Muddassir, Mohd., et al.
Publicado: (2020)

PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Author Correction: Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
por: Gao, Jing, et al.
Publicado: (2022)

Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
por: Gabizon, Ronen, et al.
Publicado: (2020)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
por: Gasic, Ivana, et al.
Publicado: (2020)

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
por: Bond, Michael J., et al.
Publicado: (2021)

First small-molecule PROTACs for G protein-coupled receptors: inducing α(1A)-adrenergic receptor degradation
por: Li, Zhenzhen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o3l5fjdl14ldju07lk8dc3lo9d